Medtronic announced the purchase of CathWorks, a developer of the FFRangio® system, for up to $585 million, including potential earn‑out payments after closing. The deal adds a non‑wire‑based fractional flow reserve (FFR) diagnostic platform that delivers real‑time physiological data from routine coronary angiograms, broadening Medtronic’s presence in the cath lab.
The FFRangio system uses computational analysis to provide FFR without a pressure wire, potentially simplifying workflow and increasing adoption of FFR in interventional cardiology. Medtronic currently offers limited FFR solutions, so the acquisition adds a complementary technology that could strengthen its cardiovascular device portfolio.
The transaction is expected to close by the end of Medtronic’s fiscal year 2026, subject to U.S. Federal Trade Commission clearance and customary regulatory approvals. Earn‑out payments will be triggered by performance targets set after closing, though specific conditions were not disclosed.
Medtronic’s strategic rationale centers on capturing a market where traditional FFR remains underutilized. By integrating CathWorks’ platform, Medtronic aims to improve decision‑making for coronary artery disease treatment and accelerate adoption of physiological assessment in routine cath‑lab practice.
The acquisition is projected to be accretive to Medtronic’s adjusted earnings per share in 2027 and beyond, reinforcing the company’s growth trajectory in cardiovascular diagnostics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.